Corcept Therapeutics Announces Appointment of Three Senior Leaders
April 07 2022 - 4:05PM
Corcept Therapeutics Incorporated (NASDAQ: CORT), a
commercial-stage company engaged in the discovery and development
of drugs to treat severe endocrine, metabolic, oncologic and
neurological disorders by modulating the effects of the hormone
cortisol, today announced the appointment of three individuals to
Commercial and Development leadership roles.
Daniel Einhorn, MD, FACP, FACE, has joined
Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has
joined as Vice President, Development Operations; and Lyndah
Dreiling, MD, has joined as Vice President, Global Oncology
Development. Dr. Einhorn will report to Sean Maduck, President of
Corcept Endocrinology. Mr. Balagtas and Dr. Dreiling will report to
Bill Guyer, PharmD, Corcept’s Chief Development Officer.
“Dan, Amiel and Lyndah bring deep and diverse
expertise to Corcept, and I am confident that their leadership
across critical commercial and development efforts will allow us to
make significant progress for patients,” said Joseph K. Belanoff,
MD, Corcept’s Chief Executive Officer. “I look forward to the
impact they will have on our ability to advance pipeline programs
and ensure our medicines reach people who could benefit from
them.”
Daniel Einhorn, MD, FACP, FACE – Vice
President, Endocrine StrategyDr. Einhorn has more than 30
years of experience as a clinical endocrinologist, lecturer,
researcher and developer of clinical practice guidelines. Prior to
joining Corcept he served as President of Diabetes and Endocrine
Associates, Medical Director of Scripps Whittier Diabetes
Institute, Past-Clinical Professor of Medicine at the University of
California San Diego and Associate Editor of the Journal of
Diabetes. Dr. Einhorn is Past-President of the American Association
of Clinical Endocrinologists and Past-President of the American
College of Endocrinology. He received his BA from Yale, his MD from
Tufts University and completed post-graduate training at the Beth
Israel Hospital, Harvard Medical School. Dr. Einhorn has been the
recipient of numerous awards and honors, including the Outstanding
Clinical Endocrinologist Award from the Endocrine Society. In 2022
he was made a Master of the American College of Endocrinology and
Fellow of the Royal Society of Medicine.
Amiel Balagtas – Vice President,
Development OperationsMr. Balagtas brings more than 30
years of scientific and operations experience to his role. He
joined Corcept after 23 years at Gilead Sciences, in roles of
increasing seniority in Clinical Operations, Marketing and Medical
Affairs. He most recently served as Executive Director, Development
Systems at Gilead. In this capacity, Mr. Balagtas led a global
team responsible for process and systems improvement across the
entire Development organization, including Portfolio Strategy &
Management, Clinical Research, Regulatory Affairs and Clinical Data
Science. Prior to Gilead, Mr. Balagtas worked as a Clinical
Trial Coordinator at Stanford and the University of California, San
Francisco, managing both pharmaceutical company and NIH-supported
clinical studies. He is a graduate of the University of
California, Los Angeles and earned his Master of Business
Administration from Golden Gate University.
Lyndah Dreiling, MD – Vice President,
Global Oncology DevelopmentDr. Dreiling is a
hematologist/oncologist who brings to Corcept more than 25 years of
experience in pharmaceutical and biotechnology drug development and
academic medicine. She joins the company from Spectrum
Pharmaceuticals, where she held the role of Senior Vice President,
Clinical Development. She has held diverse leadership positions of
increasing seniority at Amgen, Aventis, Five Prime Therapeutics and
Gilead, and has managed Clinical Operations, Clinical Pharmacology,
Safety, Biometrics and Medical teams. Over the course of her
career, Lyndah has led design, execution and interpretation of data
from Phase 1 through 3 trials, global regulatory submissions and
post-marketing studies. Dr. Dreiling holds undergraduate, MBA and
MD degrees from the University of Colorado, where she also
completed her internal medicine residency and a hematology/oncology
fellowship. About Corcept
TherapeuticsCorcept has discovered a large portfolio of
proprietary compounds that selectively modulate the effects of
cortisol and owns extensive United States and foreign intellectual
property covering both their composition and their use to treat a
variety of serious disorders. The company is conducting clinical
trials of its leading cortisol modulators as potential treatments
for patients with Cushing’s syndrome, ovarian, adrenal and prostate
cancer, weight gain caused by the use of antipsychotic medications
and liver disease. Corcept’s drug Korlym® was the first medication
approved by the U.S. Food and Drug Administration for the treatment
of patients with Cushing’s syndrome.
Forward Looking
StatementsStatements in this press release, other than
statements of historical fact, are forward-looking statements based
on our current plans and expectations that are subject to risks and
uncertainties that might cause our actual results to differ
materially from those such statements express or imply. These risks
and uncertainties include, but are not limited to, our ability to
operate our business, conduct our clinical trials and achieve our
other goals during the COVID-19 pandemic; risks related to the
development of product candidates, including their clinical
attributes, rate of advancement and timing of regulatory
submissions, mandates, oversight and other requirements; and the
scope and protective power of our intellectual property. These and
other risks are set forth in our SEC filings, which are available
at our website and the SEC’s website. In this press release,
forward looking statements include the performance of our
commercial and clinical programs and the ability of Mr. Balagtas
and Doctors Einhorn and Dreiling to contribute to them. We disclaim
any intention or duty to update forward-looking statements made in
this press release.
CONTACT:Investor
Relationsir@corcept.comwww.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024